Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05362929 · ClinicalTrials.gov registry record · NA
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
A NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation, sponsored by Albert Einstein College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT05362929: Recruiting NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation, sponsored by Albert Einstein College of Medicine.
NCT05362929 is a NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 46 participants, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05362929, a NA study of Acne Scars - Mixed Atrophic and Hypertrophic and Hyperpigmentation, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative/ablative laser for acne scarring in skin of color.
Primary Outcome
Change in acne scarring severity from baseline to nine months will be assessed using the Global Scale for Acne Scar Severity (SCAR-S) scale. The SCAR-S is a validated scale used to assess the severity of acne scarring using a 6-point scale ranging from 0 ("Clear, no visible scars from acne") to 5 ("Very Severe; entire area with prominent atrophic or hypertrophic scars") such that higher scores are indicative of more severe scarring. Two independent blinded dermatologists will rate before and aft
Conditions Studied
Interventions
- DEVICE Sciton Halo
Study Locations (1)
New York
- 555 Taxter Road - Elmsford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT05362929 shows while recruiting
NCT05362929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (56% lower).
The record links to 3 conditions, with Acne Scars - Mixed Atrophic and Hypertrophic appearing as the primary indexed condition, and to 1 intervention - of which Sciton Halo is the first listed.
NCT05362929 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05362929 about?
NCT05362929 is a clinical study titled "Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color". The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative/ablative laser for acne scarring in skin of color.
What is the current status of trial NCT05362929?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2023-10-11. Estimated completion is 2026-09.
What conditions does trial NCT05362929 study?
This clinical trial studies the following conditions: Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation, Laser-Induced Hyperpigmentation.
What interventions are being tested in trial NCT05362929?
The interventions under investigation include: Sciton Halo (DEVICE).
Who is sponsoring clinical trial NCT05362929?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05362929 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Scars - Mixed Atrophic and Hypertrophic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AVAVA MIRIA General Use
RECRUITING · NA
-
The MIRIA Acne Scar Study
ACTIVE NOT RECRUITING · NA
-
AV-23-001 AVAVA MIRIA Pilot Study
ACTIVE NOT RECRUITING · NA
-
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
COMPLETED · NA
-
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
COMPLETED · NA
-
Functional Usability and Feasibility Testing of the Profound Matrix™ System
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI